MAJOR INVESTMENTS FOR IFLS MEMBER SPIN-OUT

In February 2024 Curve Therapeutics, a spin-out company led by IfLS member Professor Ali Tavassoli, announced the conclusion of a £40.5 million Series A financing led by Pfizer Ventures. The investment will turbocharge Curve’s pioneering Microcycle® drug discovery platform and progress a pipeline of assets addressing cancer targets into the clinic.

Following a deal worth US$1.7billion, Curve is also collaborating with multinational pharmaceutical company MSD. The two companies are using the drug discovery platform to generate and screen millions of molecules to discover new medical treatments for currently ‘undruggable’ biological targets, including cancers.

Ali, a Professor of Chemical Biology, cites the University’s championing of interdisciplinary research – particularly support from Chemistry, IfLS, Research and Innovation Services and Future Worlds – as contributing to his success in commercialising his research.

Read more about Curve Therapeutics at www.curvetx.com